Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Jun 19, 2014 10:27am

219 Views

Post# 22674956

RE:many potential uses

Thanks Imtesty.

I read through the abstract and paragraphs that talk about all of the types of diseases this approach may cure and it incredible.

You'd have to by a medical bio-chemist and specialized as well in order to understand this. Perhaps biotech would have insight.

If this is RVX or Zenith as opposed to some other company it is great news because of the almost limitless possibilities. Start up those little epigenetic and get those compounds moving and start getting contracts with BP to develop compounds for them.

Thanks for the great posts.
Toinv

Bullboard Posts

Building on success: Silvercorp’s acquisition of Adventus